Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

• Status: Not yet recruiting
• Trial end date: 2024-04-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the research is to determine whether a medication called dapagliflozin will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking the medication dapagliflozin (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Minneapolis Heart Institute Foundation
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

• Patients with their first STEMI (> 18 years and < 75 years) who underwent successful primary PCI and able to give informed consent

• At least mild LV dysfunction (LVEF < 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI

• Infarct size that is > 10% of LV mass

• The presence of MVO that is > 10% of infarct size

Exclusion Criteria:

• Contraindication to cardiac MRI

• Life expectancy < 1 year

• Previous CABG or Valve Surgery

• Previous STEMI

• Pregnant or planning to become pregnant or lactating women

• Cardiogenic shock (not resolved)

• Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)

• GFR<30 ml/min/1.73m2 or end-stage renal disease on dialysis

• Type 1 diabetes mellitus or history of diabetic ketoacidosis

• Type I or II diabetes with insulin use

• Prior intolerance of SGLT2 inhibitors

• Current use of SGLT2 inhibitors

• Contraindications to gadolinium